GET DAILY SIGNALSGSK plc (GSK): Q1 2026 Earnings Deliver +5% Sales Growth and EPS Beat
Key Takeaways
- GSK plc reported Q1 2026 total sales of £7.6 billion, up 5% at constant exchange rates (CER), slightly ahead of consensus expectations.
- Core earnings per share (EPS) reached 46.5p, a 9% increase at CER, surpassing analyst estimates of around 43.5p.
- Specialty Medicines sales surged 14% at CER to £3.2 billion, fueled by HIV, oncology, and respiratory growth.
- Core operating profit rose 10% at CER to £2.65 billion, with margin expansion to 34.7%.
- Full-year 2026 guidance reaffirmed: sales growth 3%-5%, core operating profit and EPS growth 7%-9% at CER.
- Q1 dividend of 17p declared; £1.7 billion share buyback executed to date.
Earnings Context and Why It Matters
GSK plc's (GSK) Q1 2026 earnings provide critical insight into the pharmaceutical giant's transformation toward high-growth specialty medicines amid a challenging macro environment. Following a strong full-year 2025, where sales grew 7%, I'm focused on sustained momentum in key franchises like HIV and oncology, while monitoring vaccine dynamics and general medicines decline. This report matters as it validates GSK's strategy shift post-Haleon spin-off, with Specialty Medicines now over 40% of sales. Strong execution could bolster confidence in long-term 2031 targets of over £40 billion in sales, influencing valuation in a sector facing pricing pressures and R&D demands.
Q1 Reported Results
GSK delivered Q1 2026 results for the three months ended 31 March 2026, with total sales of £7,629 million, reflecting 2% growth at actual exchange rates (AER) and 5% at CER. This marked a slight beat versus consensus revenue forecasts.
Core operating profit climbed to £2,650 million, up 10% at CER, driven by volume growth, favorable product mix, and selling, general & administrative (SG&A) efficiencies, despite higher R&D spend. Core EPS of 46.5p rose 9% at CER, exceeding expectations of 43.5p, while reported EPS was 43.2p. I also checked these figures using Tickeron’s AI Screener to see how GSK stacks up against peers.
By segment, Specialty Medicines led with £3,226 million (+14% CER), including HIV at £1,824 million (+10%), Oncology £512 million (+28%), and Respiratory/Immunology & Inflammation £890 million (+16%). Vaccines posted £2,149 million (+4% CER), boosted by Shingrix (+20%). General Medicines fell to £2,254 million (-6% CER) due to portfolio normalization. Guidance for FY 2026 was reaffirmed unchanged.
Market Reaction and Investor Sentiment
GSK shares dipped modestly in early trading following the Q1 release, despite the earnings beat, as some investors appeared cautious on the reaffirmed FY 2026 guidance amid broader pharma sector pressures. Pre-earnings momentum had built on expectations of continued Specialty strength, but focus shifted to pipeline execution risks and vaccine softness in Arexvy. Sentiment remains positive on long-term growth drivers like Shingrix and HIV long-acting formulations, with analysts noting robust margins as a highlight. One thing that stands out to me is how margins continue to support the case for steady profitability.
Forward Outlook and Key Factors to Monitor
GSK's reaffirmed FY 2026 guidance signals confidence in 3%-5% sales growth, with low double-digit expansion in Specialty Medicines offsetting stable-to-declining Vaccines and General Medicines. Core operating profit and EPS are projected to grow 7%-9% at CER, supported by royalty income of £800-850 million and controlled SG&A.
I'm watching pipeline catalysts, including Q2 EASL data for bepirovirsen (potential hepatitis B cure), Phase III readouts for camlipixant (chronic cough), Jemperli (rectal cancer), and long-acting HIV PrEP. Recent approvals like Exdensur for asthma and Blenrep in China, plus acquisitions such as ozureprubart for food allergies, bolster the R&D pipeline.
Key risks include U.S. pricing dynamics, competition in vaccines, and macroeconomic factors impacting demand. Dividend progression to 70p FY and completion of the £2 billion buyback remain supportive. Track quarterly Specialty momentum and margin trends for signs of sustained execution—this is important because it will shape the path to those 2031 goals.
A Tool I Use for Stock Analysis: Tickeron’s AI Screener
One tool that’s become part of my research process is Tickeron’s AI Screener, an AI-powered stock and ETF discovery tool. It helps me filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals, scanning thousands of stocks with customizable filters like industry, market cap, and performance metrics. For stocks like GSK, it quickly surfaces trade ideas and comparisons that save time over manual screening. From what I see, it enhances my workflow for spotting opportunities efficiently.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
GSK's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for GSK moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 15 of the 23 cases the stock moved higher. This puts the odds of a move higher at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on October 15, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 25 of 45 cases over the following month. The odds of a continued upward trend are 56%.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 29 of 58 cases where GSK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 50%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In 37 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
GSK moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GSK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.578) is normal, around the industry mean (-1.476). P/E Ratio (20.488) is within average values for comparable stocks, (21.871). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.036) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and other pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement